A cancer biomarker is a biological marker which indicates the presence of cancer in the body. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers are used for diagnosis, prognosis, and epidemiology of cancer.
Because they are expressed against a person's genetic background and environmental exposure, and epigenetic events occur early in cancer development, Epigenetic biomarkers are more advantageous over other types of biomarkers.
Epigenetic biomarkers potentially have numerous clinical applications in cancer intervention and treatment and significant implications for public health.
Types of epigenetic biomarkers:
- DNA methylation, circulating or noncirculating
- MicroRNA and other noncoding RNA
- Protein markers
For e.g., DNA methylation is one of the major epigenetic mechanisms and it is a genetic feature better reflecting disease development and, consequently, has the potential to become a more conclusive biomarker for detection and diagnosis of different diseases.
Related Conference of Epigenetic Biomarker
Epigenetic Biomarker Conference Speakers
- Artificial Intelligence and Cancer
- Cancer APIs and Clinical Trials
- Cancer Case Studies
- Cancer Diagnostics and Staging
- Cancer Epigenetics
- Cancer Evolution and Research
- Cancer Genomics and Epigenomics
- Cancer Treatment, Therapy and Nursing
- Chromatin Remodeling and Cancer
- Clinical Epigenetics
- Epigenetic Biomarker
- Epigenetic Therapy
- Epigenetics and Chromatin
- Histone Modifications and Cancer